Item 8.01 Other Events.




As previously disclosed, on November 1, 2022, Benefitfocus, Inc. (the "Company")
entered into an Agreement and Plan of Merger, as amended and restated by the
Amended and Restated Agreement and Plan of Merger, dated as of December 19, 2022
(the "Merger Agreement"), by and among the Company, Voya Financial, Inc., a
Delaware corporation ("Parent") and Origami Squirrel Acquisition Corp, a
Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub").
Pursuant to the Merger Agreement, Merger Sub will be merged with and into the
Company (the "Merger"), with the Company continuing as the surviving corporation
in the Merger. On December 19, 2022, in connection with the Merger, the Company
filed with the Securities and Exchange Commission ("SEC") a definitive proxy
statement (the "Definitive Proxy Statement") with respect to the special meeting
of the Company's stockholders ("Special Meeting") scheduled to be held on
January 20, 2023. Additional information about how to attend the Special Meeting
is contained in the Definitive Proxy Statement.

Litigation Related to the Merger



As previously disclosed in the Definitive Proxy Statement, one lawsuit had been
filed in connection with the Merger between November 1, 2022 and December 16,
2022 against the Company and the directors of the Company (collectively, the
"Defendants"). The complaint, Stein v. Benefitfocus, Inc. et al., C.A. No.
1:22-cv-10358-PAE, was filed on December 7, 2022 in the United States District
Court for the Southern District of New York.

Following the filing of the Definitive Proxy Statement with the SEC, two
additional lawsuits were filed in connection with the Merger against the
Defendants. The complaint, Weiss v. Benefitfocus, Inc. et al., C.A. No.
1:22-cv-10719-PAE, was filed on December 20, 2022 in the United States District
Court for the Southern District of New York. The complaint, Ballard v.
Benefitfocus, Inc. et al., C.A. 1:22-cv-01640-UNA, was filed on December 29,
2022 in the United States District Court for the District of Delaware
(Wilmington).

The complaints filed allege that the Defendants disseminated or authorized the
dissemination of an incomplete or misleading proxy statement regarding the
proposed Merger in violation of Sections 14(a) and 20(a) of the Securities
Exchange Act of 1934 (the "Exchange Act") and SEC Rule 14a-9 promulgated
thereunder, including in respect of the disclosures concerning the Company's
financial projections and the analyses performed by the Company's financial
advisor in support of its fairness opinion. The complaints further allege that
the directors of the Company are liable for these violations as "controlling
persons" of the Company under Section 20(a) of the Exchange Act.

The complaints seek injunctive relief, including enjoining the Merger unless and
until the Defendants disclose the allegedly omitted material information and
rescinding the Merger in the event the Company consummates the Merger (or
awarding rescissory damages). The complaints also seek, among other relief,
damages and an award of attorneys' and experts' fees. The Company also has
received seven letters on behalf of purported stockholders of the Company
raising similar allegations and demanding the disclosure of certain additional
information.

The Company believes that the claims and allegations in the complaints and
stockholder letters are without merit and that no further disclosure is required
under applicable law. However, in order to avoid the risk of the claims delaying
or adversely affecting the Merger and to minimize the costs, risks, and
uncertainties inherent in litigation, and without admitting any liability or
wrongdoing, the Company has determined to voluntarily supplement the Definitive
Proxy Statement as described in this Current Report on Form 8-K. Nothing in this
Current Report on Form 8-K shall be deemed an admission of the legal necessity
or materiality under applicable laws of any of the disclosures set forth herein.
To the contrary, the Company specifically denies all allegations in the
complaints and letters and any assertion that additional disclosure was or is
required.

Supplemental Disclosures to Definitive Proxy Statement



This supplemental information to the Definitive Proxy Statement should be read
in conjunction with the Definitive Proxy Statement, which should be read in its
entirety. Nothing herein shall be deemed an admission of the legal necessity or
materiality of any of the disclosures set forth herein. All page references in
the information below are to pages in the Definitive Proxy Statement, and all
terms used but not defined below shall have the meanings set forth in the
Definitive Proxy Statement. Except as specifically noted herein, the information
set forth in the Definitive Proxy Statement remains unchanged.

The following underlined language is added to footnote 2 to the table following
the last full paragraph of the Definitive Proxy Statement entitled "The Merger
Proposal-Financial Forecasts and Financial Projections" that appears on page 68.

(2) "Unlevered Free Cash Flow" means Adjusted EBITDA less stock-based

compensation, less capital expenditures, changes in net working capital and

taxes. Unlevered Free Cash Flow from Q4 2022E to 2026E assumes no income

taxes paid as a result of the utilization of the Company's net operating

losses. Unlevered Free Cash Flow was not presented in Alternative Case 2.

--------------------------------------------------------------------------------


The following underlined language, table and corresponding footnotes are
appended below the table following the last full paragraph of the Definitive
Proxy Statement entitled "The Merger Proposal-Financial Forecasts and Financial
Projections" that appears on page 68.

The following table presents a summary of the estimated allowable usage of net
operating losses ("NOLs") and applicable marginal tax rates from 2027 to 2032.

                                    NOL Schedule (State)
                          2027E       2028E       2029E       2030E       2031E       2032E
Allowable NOL Usage(1)   $    44     $    45     $    46     $    48     $     0     $     0

                                   NOL Schedule (Federal)
Allowable NOL Usage(2)   $    35     $    36     $    37     $    38     $    26     $     0

(1) Marginal state tax rate of 6.5% is assumed.

(2) Marginal federal tax rate of 21.0% is assumed.




The following underlined language is added to the first full paragraph in the
section of the Definitive Proxy Statement entitled "The Merger Proposal-Opinion
of Benefitfocus's Financial Advisor-Selected Precedent Transaction Analysis"
that appears on page 72.

Barclays reviewed and compared the purchase prices and financial multiples paid
in selected other transactions that Barclays, based on its experience with
merger and acquisition transactions, deemed relevant. Barclays chose such
transactions based on, among other things, the similarity of the applicable
target companies in the transactions to Benefitfocus with respect to the
industry, size, mix, margins and other characteristics of their business (with
the selected transactions having occurred within the past four years and
financial information with respect to each such transaction being publicly
available at time of announcement of the applicable transaction).

The following underlined language is added to the table following the second
full paragraph in the section of the Definitive Proxy Statement entitled "The
Merger Proposal-Opinion of Benefitfocus's Financial Advisor- Selected Precedent
Transaction Analysis" that appears on page 73.

Date                                                  EV/Revenue     EV/Revenue     EV/EBITDA      EV/EBITDA           EV
Announced        Acquiror             Target             LTM            NTM            LTM            NTM        ($ in billions)
 10/3/2022    Francisco         bswift LLC               N/A            N/A            N/A            N/A              N/A
              Partners, LP
 6/21/2022    TPG, Inc.         Convey Health            3.1x           2.6x          15.7x          13.0x            $1.1
                                Solutions
                                Holdings, Inc.
 6/16/2022    Telus Corp        LifeWorks                2.9x           2.8x          15.7x          14.5x            $2.3
                                Holdings, Inc.
 1/5/2022     Vera Whole        Castlight Health,        2.2x           2.2x          20.9x           N/A             $0.3
              Health, Inc.      Inc.
 12/1/2021    Stone Point       Businessolver.com,       N/A            N/A            N/A            N/A              N/A
              Capital LLC       Inc.
 4/4/2021     Wex, Inc.         Benefit Express          N/A            N/A            N/A            N/A             $0.3
                                Services, LLC
 1/25/2021    Foley Trasimene   Alight Solutions         2.7x           2.6x          13.3x          12.2x            $7.3
              Acquisition       LLC
              Corp.
10/27/2020    Teleperformance   Health Advocate,         4.9x           4.5x          13.9x          12.1x            $0.7
              S.A.              Inc.
 7/28/2020    TA Associates     Edifecs, Inc. (51%       N/A            N/A

           N/A            N/A              N/A
              Management,       stake)
              L.P./Francisco
              Partners, LP


--------------------------------------------------------------------------------

Date                                       EV/Revenue    EV/Revenue     EV/EBITDA     EV/EBITDA          EV
Announced      Acquiror        Target          LTM           NTM           LTM           NTM       ($ in billions)
11/25/2019   Securian        Empyrean          N/A           N/A           N/A           N/A             N/A
             Financial       Capital
             Services,       Partners,
             Inc.            LP
6/27/2019    HealthEquity,   WageWorks,       3.2x          3.1x          10.8x         11.0x           $1.5
             Inc.            Inc.
1/17/2019    WEX, Inc.       Discovery        4.3x           N/A          21.3x          N/A            $0.4
                             Benefits,
                             Inc.
                             Mean             3.3x          3.0x          15.9x         12.5x           $1.7
                             Medium           3.1x          2.7x          15.7x         12.2x           $0.9


The following underlined language is added to the second full paragraph in the
section of the Definitive Proxy Statement entitled "The Merger Proposal-Opinion
of Benefitfocus's Financial Advisor-Discounted Cash Flow Analysis" that appears
on page 74.

To calculate the estimated enterprise value of Benefitfocus using the discounted
cash flow method, Barclays added (i) Benefitfocus's projected after-tax
Unlevered Free Cash Flows for the last quarter of fiscal year 2022 and for
fiscal years 2023 through 2026 based on the Management Case and (ii) the
"terminal value" of Benefitfocus as of the end of fiscal year 2026, and
discounted such amount to its present value using a mid-year convention and a
range of selected discount rates. The after-tax Unlevered Free Cash Flows is
Benefitfocus's Adj. EBITDA less stock-based compensation, less capital
expenditures and adjusting for changes in net working capital and taxes. The
residual value of Benefitfocus at the end of the forecast period, or "terminal
value," was estimated by selecting a range of estimated LTM Adj. EBITDA exit
multiples. Barclays assumed a range of terminal value LTM Adj. EBITDA exit
multiples of 9.5x to 11.5x, which was derived by Barclays utilizing its
professional judgment and experience, taking into account the results from the
selected comparable companies analysis and applying such range to the Management
Case. The range of after-tax discount rates of 11.0% to 13.0% was selected based
on an analysis of the weighted average cost of capital of Benefitfocus, which
was derived by applying the Capital Asset Pricing Model and took into account
certain metrics including the beta of the Company, market risk premium, cost of
debt and marginal tax rate. Barclays then calculated a range of implied prices
per share of Benefitfocus by subtracting estimated net debt of $(143.0 million)
as of September 30, 2022 and the value of Benefitfocus's outstanding Preferred
Stock (at liquidation value) of $80.0 million, in each case as provided by
Benefitfocus's management, and adding the present value of tax savings post-2026
in the amount of $23.0 million from Benefitfocus's net operating losses derived
from the Management Case using the discounted cash flow method to the estimated
enterprise value and dividing such amount by the fully diluted number of shares
of Common Stock as of October 31, 2022 (comprised of 34.4 million shares of
Common Stock outstanding, 4.2 million Company RSUs and Company PRSUs outstanding
and 0.1 million outstanding Company Options with a weighted average exercise
price of $13.53, in each case as provided by Benefitfocus's management). Based
on its professional judgment and experience, Barclays selected a discount rate
of 12% to calculate the present value of Benefitfocus's tax savings post-2026.
The following summarizes the result of these calculations:

The following underlined language is added to, and the crossed out language is deleted from, the first paragraph in the section of the Definitive Proxy Statement entitled "The Merger Proposal-Opinion of Benefitfocus's Financial Advisor-Equity Research Target Prices Review" that appears on page 75.



Barclays reviewed publicly available one-year forward price targets for the
Common Stock prepared and published by three equity research firms William
Blair, KeyBanc Capital Markets and Piper Sandler that covered Benefitfocus as of
October 31, 2022. The price targets published by the equity research firms did
not necessarily reflect current market trading prices for the Common Stock.
Barclays noted that the range of low to high one-year forward share price
targets as of October 31, 2022 was $6.00 to $10.00 per share.

The following underlined language is added to the second full paragraph in the
section of the Definitive Proxy Statement entitled "The Merger Proposal-Opinion
of Benefitfocus's Financial Advisor-General" that appears on page 77.

Barclays is acting as financial advisor to Benefitfocus in connection with the
Merger. As compensation for its services in connection with the Merger, Barclays
is entitled to a fee from Benefitfocus of $1.0 million, payable upon the
delivery of Barclays's opinion, which is referred to as the "Opinion Fee." The
Opinion Fee was not contingent upon the conclusion of Barclays's opinion or the
consummation of the Merger. Additional compensation of approximately
$11.11 million will be payable by Benefitfocus upon completion of the
Merger (against which the amount of the Opinion Fee as well as $250,000 of

--------------------------------------------------------------------------------
advisory fees previously earned by Barclays will be credited). In addition,
Benefitfocus has agreed to reimburse Barclays for its reasonable out-of-pocket
expenses incurred in connection with the Merger and to indemnify Barclays for
certain liabilities that may arise out of its engagement by Benefitfocus and the
rendering of Barclays's opinion. Barclays has performed various investment
banking and financial services for Benefitfocus and Voya in the past, and is
likely to perform such services in the future, and has received, and is likely
to receive, customary fees for such services. Specifically, in the past two
years, the aggregate fees received by Barclays from Benefitfocus or invoiced
(but not yet received) by Barclays to Benefitfocus for activism preparedness
advisory services and other transaction-related advisory services were
approximately $3.25 million (excluding the Opinion Fee and the fees payable to
Barclays upon consummation of the Merger). In the past two years, Barclays has
not performed any investment banking services for Voya for which it has received
any fees.

Cautionary Statement Regarding Forward-Looking Statements



Certain statements in this communication may constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Exchange Act, each as amended. Forward-looking statements are
often identified by the use of words such as, but not limited to, "anticipate,"
"believe," "can," "continue," "could," "estimate," "expect," "intend," "may,"
"might," "will," "plan," "project," "seek," "should," "target," "would," and
similar expressions or variations intended to identify forward-looking
statements. These statements are based on the beliefs and assumptions of our
management based on information currently available to management.

Such forward-looking statements are subject to risks, uncertainties and other
important factors that could cause actual results and the timing of certain
events to differ materially from future results expressed or implied by such
forward-looking statements. Factors that could cause or contribute to such
differences include the following: (i) conditions to the completion of the
proposed transaction, including stockholder approval of the proposed
transaction, might not be satisfied on the terms expected or on the anticipated
schedule; (ii) the occurrence of any event, change or other circumstance that
could give rise to the termination of the Merger Agreement between the parties
to the proposed transaction; (iii) the effect of the announcement or pendency of
the proposed transaction on the Company's customers, suppliers, business
relationships, operating results and business generally; (iv) the risk that the
proposed transaction disrupts the Company's current plans and operations and the
potential difficulties in the Company's employee retention as a result of the
proposed transaction; (v) the risk related to diverting management's attention
from our ongoing business operations; (vi) potential litigation that has been
and may be instituted against the Company or its directors or officers related
to the proposed transaction or the Merger Agreement between the parties to the
proposed transaction; (vii) the amount of the costs, fees, expenses and other
charges related to the proposed transaction; (viii) the risk that the proposed
transaction will not be consummated in a timely manner; and (ix) such other
factors as are set forth in the Company's periodic public filings with the SEC,
including but not limited to those described under the headings "Risk Factors"
and "Forward Looking Statements" in its Form 10-K, as amended for the fiscal
year ended December 31, 2021 and in its other filings made with the SEC from
time to time, which are available via the SEC's website at www.sec.gov.

The Company's forward-looking statements speak only as of the date of this
communication or as of the date they are made. The Company disclaims any intent
or obligation to update any "forward looking statement" made in this
communication to reflect changed assumptions, the occurrence of unanticipated
events or changes to future operating results over time.

Additional Information and Where to Find It



This communication may be deemed to be solicitation material in respect of the
proposed acquisition of the Company by Parent. In connection with the proposed
acquisition, the Company has filed with the SEC and furnished to its
stockholders the Definitive Proxy Statement and other relevant documents.
STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH
THE SEC, INCLUDING THE COMPANY'S PROXY STATEMENT, BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. Investors and security holders
will be able to obtain the documents free of charge at the SEC's web site,
http://www.sec.gov, and the Company's stockholders will receive information at
an appropriate time on how to obtain transaction-related documents free of
charge from the Company.

Participants in Solicitation



The Company and its directors and executive officers may be deemed to be
participants in the solicitation of proxies from the Company's stockholders in
respect of the proposed acquisition. Information about the directors and
executive officers of the Company is set forth in the proxy statement for the
Company's 2022 Annual Meeting of Stockholders, which was filed with the SEC on
May 9, 2022. Investors may obtain additional information regarding the interest
of such participants by reading the Definitive Proxy Statement regarding the
proposed transaction.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses